Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Oct / Poisoning Pain
Discovery & Development Drug Discovery Research News

Poisoning Pain

Investigating the pain-relieving properties of spider venom

By Maryam Mahdi 10/28/2020 1 min read Quick Read (pre 2022)

Share

Offering an alternative to conventional analgesics, newly published research suggests that two compounds derived from the venom of the Venezuelan Pinkfoot Goliath tarantula could be useful in managing pain associated with irritable bowel syndrome (IBS) (1).

IBS affects up to 11 percent of the world’s population (1). Symptoms include constipation and/or diarrhea, and abdominal pain, which can be severe. NSAIDs and opioids have been tested as pain management solutions, but have proved ineffective for most patients.

“Historically, treatments for IBS have focused on trying to normalize the effects of the condition on gastrointestinal motility, but this has had little effect on visceral (internal organ) pain” says Stuart Brierley, a professor at Flinders University, Australia, and the project’s co-lead, adding: “Furthermore, opioids cause constipation, which poses significant problems for patients who already suffer from it. These types of drugs also fail to target both the gastrointestinal tract and the nerves that send pain signals from the gut to the brain.”

The team chose to investigate tarantula venoms based on earlier studies that indicated their potential for blocking specific ion channels involved in visceral pain. “We screened a broad range of spider venoms using high-throughput sodium channel assays,” says Richard Lewis, a professor from The University of Queensland’s Institute for Molecular Bioscience and co-lead on the project. “Our study identified two novel peptides in the venom of the Venezuelan Pinkfoot Goliath tarantula that block Nav1.7 – a sodium channel ion expressed in pain-sensing neurons.”

The researchers also found that the spider venom-derived compounds were capable of inhibiting calcium channel pain targets, including Cav3.2. According to Lewis, this combination “was particularly useful in reversing IBS pain.” Next, the team hopes to optimize the structure of the compounds to improve their activity at pain targets and reduce side effects.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. FC Cardoso et al., Pain [Online ahead of print] (2020). DOI:10.1097/j.pain.0000000000002041 

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Antibiotics: Going With the Flow
Drug Discovery Small Molecules
Antibiotics: Going With the Flow

April 2, 2025

2 min read

How fluid flow through the body can affect the ways in which antibiotics work.

Combatting the Side Effects of Treatments for Parkinson’s
Drug Discovery Small Molecules
Combatting the Side Effects of Treatments for Parkinson’s

April 7, 2025

4 min read

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.